About the Program:
Program Overview:
As many as 7 million people worldwide are infected with both HIV and HCV. Because of the potential consequences of HCV infection, clinicians who care for HIV/HCV co-infected patients face many complex treatment issues, including when to start treatment, which treatments to use, how long to treat patients, and which treatments can be safely combined in this population. In addition, they must remain abreast of rapidly changing information on the treatment of HIV/HCV co-infected patients. This program, "Managing HCV in HIV-positive Patients: What Clinicians Need to Know," is a series of six internet symposia, each covering a specific topic in the treatment of HIV/HCV co-infected patients. Each one hour symposium will feature an interview of an expert in the field of HCV treatment, who will review and discuss the most essential information and data HIV clinicians need to know.
The sixth and final program from this series is being brought to you from San Francisco, California and will cover, New and Future Treatment Options. This one-hour program will feature an interview of Nezam Afdhal, MD, from the Harvard School of Medicine and one of the leading experts on HCV management and treatment, by Mark Sulkowski, MD, from Johns Hopkins University.
Target Audience:
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV and HCV infection.
Learning Objectives:
After completing this activity, the participant should be better able to:
- Appropriately screen patients for HCV to identify HIV/HCV co-infected patients in their practice
- Develop effective strategies for treating HCV in HIV-positive patients
- Apply the most recent information to the treatment of HIV/HCV co-infected patients to avoid drug-drug interactions, minimize adverse effects,
and achieve successful outcomes
Release Date: January 19, 2016
Expiration Date: January 19, 2017
Estimated time to complete this program: 1 hour
Media: Internet
Faculty:
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to provideing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commerical interest.
Nezam Afdhal, MD
- Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Janssen, Roivant, Co-Crystal, Shionogi
- Research Support: Gilead, Abbvie, BMS
- Employee/Salary: Spring Bank Pharmaceuticals
- Other: Director-TRIO Healthcare
- Stock: Allurion, Gilead, Spring Bank Pharmaceuticals
Mark Sulkowski, MD
- Consulting Fees: Abbive, BMS, Janssen, Gilead, Merck
- Contracted Research: Achillion, Abbvie, BMS, Janssen, Gilead
The planners and managers reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or
participate in planning CME/CE activities in a manner that may affect
content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP
and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their
spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interests
related to the content of this CME/CE activity of any amount during the past 12 months.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period, January 19, 2016 through January 19, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10698.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Back to Top
Disclosure of Unlabeled Use
This
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
The
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
*Greenwich Mean Time
|